Market Place
Sourcing Support
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte
20 Sep 2024 //
PR NEWSWIRE
Biosyngen Presents SUPER-T Technology At ESMO 2024
19 Sep 2024 //
PR NEWSWIRE
Biosyngen`s CAR-T Asset for Solid Tumors Enters Phase II, Data Debut at ESMO
18 Sep 2024 //
PR NEWSWIRE
Biosyngen`s BRG01 Receives FDA Approval for Phase II Clinical Trial
12 Aug 2024 //
PR NEWSWIRE
Biosyngen partners with Singapore`s A*STAR to advance autoimmune therapy
02 Aug 2024 //
BIOSPECTRUM ASIA
Biosyngen`s BRG01 Enters Phase II For EBV-Specific CAR-T Therapy
16 Jul 2024 //
PR NEWSWIRE
Biosyngen Announces FDA Fast Track Designation for BST02
01 Feb 2024 //
PR NEWSWIRE
Biosyngen`s BST02 is Granted an IND Approval by FDA
26 Oct 2023 //
PR NEWSWIRE
Biosyngen received the APCGTEA 2023
18 Sep 2023 //
PR NEWSWIRE
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03
11 Sep 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.